Loading...
•
Sep 30, 2024
Theravance Q3 2024 Earnings Report
Theravance Biopharma reported strong YUPELRI demand, driving quarterly net sales to an all-time high, and reaffirmed CYPRESS development timelines.
Key Takeaways
Theravance Biopharma reported financial and operational results for the third quarter of 2024, highlighting strong YUPELRI demand and progress on the CYPRESS study. The company also announced the formation of a Strategic Review Committee to assess alternatives to unlock shareholder value.
Achieved a strong quarter for YUPELRI demand through collaboration with Viatris.
Quarterly net sales reached an all-time high.
Reaffirmed development timelines for CYPRESS.
Formed a Strategic Review Committee to assess alternatives to unlock shareholder value.
Theravance
Theravance
Theravance Revenue by Segment
Revenue by Segment
YUPELRI Collaboration Revenue
CapyFin.com Forward Guidance
Theravance Biopharma has not set a timetable for completion of the strategic review process, and it does not intend to disclose further developments unless and until it determines that such disclosure is appropriate or necessary.